Prognostic significance of pleural tumour burden in patients with malignant pleural effusions Source: Annual Congress 2010 - 100 years of thoracoscopy: still room for improvement? Year: 2010
Diagnostic value and prognostic significance of pleural C-reactive protein in lung cancer with malignant pleural effusions Source: Annual Congress 2012 - Instructive clinical aspects of thoracic oncology Year: 2012
Prognostic characteristics of malignant pleural mesothelioma Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017
Utility of serum soluble mesothelin as a follow-up marker in patients with malignant pleural mesothelioma Source: Annual Congress 2007 - Biology of thoracic malignancies Year: 2007
Comparison between mesothelin and fibulin-3 detection in pleural malignant mesothelioma (MPM) patients Source: International Congress 2016 – Mesothelioma and malignant pleural disease Year: 2016
Prognostic role of inflammatory cells in blood, pleural fluid and tumour samples, in patients with malignant pleural mesothelioma (MPM) Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017
Diagnostic value of pleural fluid angiopoietin-2 (Ang-2) levels, to differentiate malignant pleural effusions from benign pleural effusions Source: International Congress 2016 – Mesothelioma and malignant pleural disease Year: 2016
Prognostic factors in diffuse malignant pleural mesothelioma Source: Eur Respir J 2007; 30: Suppl. 51, 755s Year: 2007
Prognostic factors in diffuse malignant pleural mesothelioma Source: Eur Respir J 2003; 22: Suppl. 45, 62s Year: 2003
Diagnostic utility of pleural CEA and CYFRA 21-1 for malignant pleural effusions Source: Eur Respir J 2003; 22: Suppl. 45, 60s Year: 2003
Detection of mesothelin in the pleural effusion has a higher diagnostic utility than in serum for diagnostic of malignant mesothelioma Source: Annual Congress 2013 –Clinical problems in mediastinal and pleural malignacies Year: 2013
Clinical significance of CEA, NSE, CYFRA 21-1 in serum and pleural fluid for the diagnosis of malignant pleural effusion associated with primary lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 528s Year: 2004
Diagnostic and prognostic significance of survivin levels in malignant pleural effusion Source: Annual Congress 2011 - Molecular markers: diagnosis and management of malignant pleural effusions Year: 2011
Prognostic value of treatment outcomes patients with malignant pleural mesothelioma Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010
Evaluation of pleural fluid human epididymis 4 (HE4) as a marker of malignant pleural effusions Source: Annual Congress 2012 - Diagnosis and biology of malignant pleural effusions Year: 2012
Clinical role of pleural effusion MMP-3 levels in malignant pleural mesothelioma Source: Annual Congress 2012 - Biology and treatment of malignant pleural effusions Year: 2012
The radiologic evidance in distinguishing the pleural mesothelioma from the pleural metastatic adenocarcinoma Source: Eur Respir J 2006; 28: Suppl. 50, 93s Year: 2006
Expression of human mammaglobin gene in pleural effusion of patients affected by malignant pleural mesothelioma (MM) Source: Eur Respir J 2004; 24: Suppl. 48, 81s Year: 2004
The usefulness of Cyfra 21-1 as a disease marker in malignant pleural mesothelioma (MPM) Source: Eur Respir J 2006; 28: Suppl. 50, 85s Year: 2006
The presence of human mammaglobin transcripts in the pleural effusion is not predictive of survival in patients with malignant mesothelioma Source: Annual Congress 2008 - Biology in thoracic tumours Year: 2008